What is the 13F Pro Quality Score for QURE?

13F Pro ranks uniQure N.V. (QURE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View QURE's current score at https://13fpro.ai/research/QURE (free sign-up required for the full ranking).

Which hedge funds own the most QURE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of QURE include Avoro Capital Advisors, abrdn plc, TWO SIGMA INVESTMENTS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/QURE as soon as new 13F filings post.

Where does 13F Pro source QURE data?

All uniQure N.V. fundamentals and ownership data come directly from SEC EDGAR. uniQure N.V. files with the SEC under CIK 1590560. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is QURE in?

uniQure N.V. (QURE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is QURE research updated on 13F Pro?

QURE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

uniQure N.V.(QURE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1590560 QURE stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

QURE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for uniQure N.V. (QURE), a Healthcare sector company. QURE is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), uniQure N.V. reports quarterly revenue of $3.6M, net income of $-53.5M, free cash flow of $-38.4M. Top institutional holders of QURE by reported 13-F value include Avoro Capital Advisors, abrdn plc, TWO SIGMA INVESTMENTS,, based on the most recent SEC filings. QURE trades on the Nasdaq exchange and files with the SEC under CIK 1590560. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QURE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for uniQure N.V. directly from SEC EDGAR.

Revenue

Q1 2026

$3.6M

Net Income

Q1 2026

$-53.5M

Free Cash Flow

Q1 2026

$-38.4M

ROIC

Q1 2026

-22.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-40.6% YoY

$16.1MFY 2025

FY22 $106.5MFY23 $15.8MFY24 $27.1MFY25 $16.1M

Net Income

+16.9% YoY

$-199.0MFY 2025

FY22 $-126.8MFY23 $-308.5MFY24 $-239.6MFY25 $-199.0M

Operating Income

-0.6% YoY

$-185.3MFY 2025

FY22 $-143.2MFY23 $-282.9MFY24 $-184.3MFY25 $-185.3M

EPS (Diluted)

+29.7% YoY

$-3.46FY 2025

FY22 $-2.71FY23 $-6.47FY24 $-4.92FY25 $-3.46

Total Assets

+48.2% YoY

$824.9MFY 2025

FY22 $705.0MFY23 $831.7MFY24 $556.5MFY25 $824.9M

Total Debt

+8.9% YoY

$71.9MFY 2025

FY22 $144.5MFY23 $147.6MFY24 $66.0MFY25 $71.9M

Op. Cash Flow

+2.6% YoY

$-178.0MFY 2025

FY22 $-145.1MFY23 $-145.9MFY24 $-182.7MFY25 $-178.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$16.1M -40.6%	$27.1M +71.2%	$15.8M -85.1%	$106.5M +183.8%	$37.5M +415.2%	$7.3M
Net Income	$-199.0M +16.9%	$-239.6M +22.3%	$-308.5M -143.3%	$-126.8M	—	—
Operating Income	$-185.3M -0.6%	$-184.3M +34.8%	$-282.9M -97.6%	$-143.2M -14.1%	$-125.4M -3.5%	$-121.1M
EPS (Diluted)	$-3.46 +29.7%	$-4.92 +24.0%	$-6.47 -138.7%	$-2.71 +3.6%	$-2.81 +9.6%	$-3.11
Total Assets	$824.9M +48.2%	$556.5M -33.1%	$831.7M +18.0%	$705.0M +107.1%	$340.4M -24.1%	$448.6M
Total Debt	$71.9M +8.9%	$66.0M -55.3%	$147.6M +2.1%	$144.5M +240.7%	$42.4M -8.9%	$46.5M
Operating Cash Flow	$-178.0M +2.6%	$-182.7M -25.2%	$-145.9M -0.6%	$-145.1M -7.6%	$-134.8M -36.6%	$-98.7M

AI Insight: QURE Financial Trends

uniQure shows persistent operational losses with volatile revenue ranging $2-11M and significant cash burn across all quarters.

• Revenue remained volatile between $2M-$11M with no clear growth trajectory across 8 quarters.

• Operating losses consistently high, ranging from $-39M to $-51M in recent quarters.

• Total debt decreased from $103M in Q2 2024 to $50M in Q1 2026.

• Equity improved from negative $-7M in Q4 2024 to $149M in Q1 2026.

⚠ Operating cash flow deteriorated sharply from $-16M in Q3 2025 to $-78M in Q4 2025.

⚠ Equity volatility with swings from negative to over $200M suggests significant capital events.

AI Insight: QURE Ratio Trends

ROIC deteriorated significantly from -72.7% in Q3 2025 to -91.8% in Q1 2026, indicating worsening capital efficiency.

• ROIC worsened from -72.7% in Q3 2025 to -91.8% in Q1 2026, showing declining capital efficiency.

• Debt-to-equity ratio improved from 1.53 in Q1 2025 to 0.33 in Q1 2026, reducing leverage.

• ROE remained deeply negative at -143.4% in Q1 2026 versus -74.6% in Q4 2025.

⚠ Sparse operating and net profit margin data limits visibility into operational efficiency trends.

⚠ Persistent negative returns across all profitability metrics signal ongoing cash burn challenges.

Get alerted when QURE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for uniQure N.V. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of QURE

Avoro Capital Advisors LLC
$97.4M5,959,595 sh
abrdn plc
$86.8M5,306,386 sh
TWO SIGMA INVESTMENTS, LP
$43.8M2,675,871 sh
Nantahala Capital Management, LLC
$42.5M2,600,000 sh
RTW INVESTMENTS, LP
$42.3M2,586,356 sh
STATE STREET CORP
$37.0M2,260,512 sh
CITIGROUP INC
$36.3M2,219,100 sh
ORBIMED ADVISORS LLC
$34.9M2,136,149 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$34.0M2,079,900 sh
Caption Management, LLC
$31.6M1,930,400 sh

Fund	Value	Shares
Avoro Capital Advisors LLC	$97.4M	5,959,595
abrdn plc	$86.8M	5,306,386
TWO SIGMA INVESTMENTS, LP	$43.8M	2,675,871
Nantahala Capital Management, LLC	$42.5M	2,600,000
RTW INVESTMENTS, LP	$42.3M	2,586,356
STATE STREET CORP	$37.0M	2,260,512
CITIGROUP INC	$36.3M	2,219,100
ORBIMED ADVISORS LLC	$34.9M	2,136,149
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$34.0M	2,079,900
Caption Management, LLC	$31.6M	1,930,400

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put QURE on your watchlist

Track score changes the day uniQure N.V. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is QURE a good stock to buy?

13F Pro's AI-powered analysis of uniQure N.V. (QURE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QURE are available on the QURE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own QURE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QURE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of uniQure N.V.'s investment landscape.